Search Results

The pharmaceutical industry has experienced an extraordinary rise in the generation and use of enormous datasets. Nevertheless, there remain great challenges on this front regarding everything from target identification to understanding the performance of marketed products. In the context of this broad impact, we have assembled a group of leading researchers and executives from the MIT-connected community who will address questions of discovery, data integration, and system perturbation analysis, including use of artificial intelligence and machine learning techniques. What is the impact of current developments on high-throughput profiling, computational biology, and validation of gene targets? How do these developments impact the use of chemical libraries, drug-delivery systems, and patient-facing objectives? These are the types of questions that will be addressed in this exciting panel discussion.

Transistor footprint scaling is rapidly approaching its limits. But this is not about to slow the rapid progress of information processing technology. On the contrary, 3D integration involving new material systems and devices opens a new era with unprecedented promise.